AstraZeneca PLC
AZN | IL
Overview
Corporate Details
- ISIN(s):
- GB0009895292 (+925 more)
- LEI:
- PY6ZZQWO2IZFZC3IOL08
- Country:
- United Kingdom
- Address:
- 1 FRANCIS CRICK AVENUE, CB2 0AA CAMBRIDGE
- Website:
- https://www.astrazeneca.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
We are a global, science-led, patient-focused pharmaceutical company. We are tireless in seeking to realise the potential of what science can do. We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally. We have three priorities designed to deliver our growth through innovation strategy. Oncology We are leading a revolution in oncology to redefine cancer care. Our ambition is to provide cures for cancer in every form. BioPharmaceuticals We want to change the lives of billions of people living with chronic diseases for the better. Rare Disease Our mission is to transform the lives of people affected by rare diseases and devastating conditions.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-15 16:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 25.9 KB | |
| 2025-08-15 09:05 |
Major Shareholding Notification
|
Swedish | 10.9 KB | |
| 2025-08-12 16:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 25.7 KB | |
| 2025-08-12 09:36 |
Major Shareholding Notification
|
Swedish | 10.9 KB | |
| 2025-08-01 16:00 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 8.9 KB | |
| 2025-07-29 08:00 |
Earnings Release
H1 and Q2 2025 results
|
English | 911.5 KB | |
| 2025-07-29 08:00 |
Interim Report
|
English | 1.5 MB | |
| 2025-07-24 08:00 |
Regulatory News Service
Gefurulimab nanobody met Phase III endpoints
|
English | 20.4 KB | |
| 2025-07-22 08:00 |
Regulatory News Service
AstraZeneca plans to invest $50bn in the US
|
English | 14.2 KB | |
| 2025-07-16 08:00 |
Regulatory News Service
Update on anselamimab in AL amyloidosis
|
English | 23.0 KB | |
| 2025-07-14 08:00 |
Earnings Release
Baxdrostat met primary endpt in BaxHTN PhIII trial
|
English | 32.0 KB | |
| 2025-07-04 08:00 |
Legal Proceedings Report
Imfinzi approved in the EU for bladder cancer
|
English | 25.0 KB | |
| 2025-07-01 16:00 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 8.9 KB | |
| 2025-06-24 08:00 |
Regulatory News Service
Datroway approved in US for EGFRm lung cancer
|
English | 33.4 KB | |
| 2025-06-12 12:54 |
Prospectus
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt)
|
English | 1.3 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-13 | Philip Broadley | Other | Buy | 980 | 99,665.12 EUR |
| 2024-03-08 | Pascal Soriot | Other | Other | 105,238 | N/A |
| 2024-03-05 | Pascal Soriot | Other | Other | 17,702 | N/A |
| 2024-03-04 | Pascal Soriot | Other | Other | 109,872 | 11,076,196.32 EUR |
| 2024-03-04 | Aradhana Sarin | Other | Other | 59,125 | 5,960,391.25 EUR |
| 2023-12-12 | Anna Manz | Other | Buy | 487 | 49,623.16 EUR |
| 2023-11-22 | Michel Demare | Other | Buy | 1,000 | 101,700.00 EUR |
| 2023-11-21 | Michel Demare | Other | Buy | 1,000 | 101,052.24 EUR |
| 2023-04-28 | Michel Demare | Other | Buy | 2,000 | 234,020.00 EUR |
| 2023-03-23 | Pascal Soriot | Other | Other | 138,093 | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |